Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: IDYA stock price vs DOC: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at DOC's multiple
Needs DOC P/S.
Implied fair value · at IDYA's multiple
Needs IDYA P/S.
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: IDYA FY 2025 (ended Dec 31, 2025) · DOC FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
IDEAYA Biosciences, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Healthpeak Properties, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.08x
1.31x
Net debt / EBITDA
Leverage against operating earnings
4.97x
14.52x
Cash and equivalents
Liquid reserves on the balance sheet
$639.39M
$467.46M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Zentalis Pharmaceuticals, Inc.
IDYA vs ZNTL
Blueprint Medicines Corp
IDYA vs BPMC
Jazz Pharmaceuticals plc
IDYA vs JAZZ
Sarepta Therapeutics, Inc.
IDYA vs SRPT
WELLTOWER INC.
IDYA vs WELL
Ventas, Inc.
IDYA vs VTR
ALEXANDRIA REAL ESTATE EQUITIES, INC.
IDYA vs ARE
SL GREEN REALTY CORP
IDYA vs SLG
$84.13M
$9.85B
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
